Novartis AG Return on Tangible Equity 2010-2022 | NVS

Current and historical return on tangible equity values for Novartis AG (NVS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Novartis AG Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-06-30 $22.98B $0.53B -1915.17%
2022-03-31 $24.18B $-2.79B -612.95%
2021-12-31 $24.02B $4.05B -350.99%
2021-09-30 $9.81B $-6.59B -94.38%
2021-06-30 $8.98B $-10.46B -76.73%
2021-03-31 $7.96B $-14.38B -65.93%
2020-12-31 $8.07B $-10.14B -65.50%
2020-09-30 $7.10B $-11.86B -73.01%
2020-06-30 $7.21B $-11.88B -94.69%
2020-03-31 $12.14B $-15.41B -233.24%
2019-12-31 $11.73B $0.24B -410.89%
2019-09-30 $11.80B $-3.40B -676.14%
2019-06-30 $11.38B $-2.25B 3140.14%
2019-03-31 $12.35B $-6.01B 824.70%
2018-12-31 $12.61B $4.68B 297.41%
2018-09-30 $13.39B $5.03B 216.33%
2018-06-30 $13.85B $2.29B 187.47%
2018-03-31 $8.06B $4.96B 94.41%
2017-12-31 $7.70B $12.48B 90.31%
2017-09-30 $6.68B $9.82B 78.15%
2017-06-30 $6.54B $6.90B 74.24%
2017-03-31 $6.37B $4.92B 70.46%
2016-12-31 $6.71B $12.57B 72.06%
2016-09-30 $6.81B $10.86B 74.79%
2016-06-30 $6.76B $7.79B 74.41%
2016-03-31 $6.79B $6.03B 67.65%
2015-12-31 $17.78B $11.73B 164.59%
2015-09-30 $18.22B $10.77B 148.16%
2015-06-30 $19.56B $11.60B 139.93%
2015-03-31 $20.27B $9.11B 135.52%
2014-12-31 $10.21B $17.70B 65.28%
2014-09-30 $10.75B $17.48B 71.10%
2014-06-30 $9.76B $15.55B 70.38%
2014-03-31 $9.72B $11.84B 78.45%
2013-12-31 $9.18B $15.61B 82.69%
2013-09-30 $9.13B $12.47B 99.75%
2013-06-30 $9.29B $9.65B 126.25%
2013-03-31 $9.42B $6.66B 160.62%
2012-12-31 $9.27B $7.84B 202.71%
2012-09-30 $8.29B $5.28B 228.95%
2012-06-30 $8.36B $3.68B 281.75%
2012-03-31 $8.42B $1.49B 330.79%
2011-12-31 $8.94B $4.03B 411.27%
2011-09-30 $10.11B $2.67B 424.98%
2011-06-30 $9.92B $1.98B 503.32%
2011-03-31 $9.63B $0.01B 95.89%
2010-12-31 $9.79B $4.85B 53.08%
2010-09-30 $9.93B $1.04B 38.17%
2010-06-30 $9.75B $34.28B 29.12%
2010-03-31 $9.37B $33.65B 28.93%
2009-12-31 $8.40B $35.09B 27.51%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84